{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T17:28:34Z","timestamp":1787506114925,"version":"build-2736575974"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,4,18]],"date-time":"2023-04-18T00:00:00Z","timestamp":1681776000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002920","name":"Research Grants Council, University Grants Committee","doi-asserted-by":"publisher","award":["N_HKU767\/22"],"award-info":[{"award-number":["N_HKU767\/22"]}],"id":[{"id":"10.13039\/501100002920","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002920","name":"Research Grants Council, University Grants Committee","doi-asserted-by":"publisher","award":["PF18\u201313277"],"award-info":[{"award-number":["PF18\u201313277"]}],"id":[{"id":"10.13039\/501100002920","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003452","name":"Innovation and Technology Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003452","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005407","name":"Food and Health Bureau","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005407","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005847","name":"Health and Medical Research Fund","doi-asserted-by":"publisher","award":["HMRF 20190582"],"award-info":[{"award-number":["HMRF 20190582"]}],"id":[{"id":"10.13039\/501100005847","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1016\/j.jconrel.2023.04.029","type":"journal-article","created":{"date-parts":[[2023,4,30]],"date-time":"2023-04-30T05:08:40Z","timestamp":1682831320000},"page":"128-141","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"special_numbering":"C","title":["Neutralisation of SARS-CoV-2 by monoclonal antibody through dual targeting powder formulation"],"prefix":"10.1016","volume":"358","author":[{"given":"Han Cong","family":"Seow","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian-Piao","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harry Weijie","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cuiting","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kun","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianwen","family":"Situ","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hehe","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan W.S.","family":"Leung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuofeng","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenny K.W.","family":"Lam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jconrel.2023.04.029_bb0005","doi-asserted-by":"crossref","first-page":"3618","DOI":"10.1038\/s41467-022-31395-0","article-title":"Contribution of low population immunity to the severe omicron BA.2 outbreak in Hong Kong","volume":"13","author":"Chen","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jconrel.2023.04.029_bb0010","doi-asserted-by":"crossref","first-page":"65","DOI":"10.31083\/j.fbl2702065","article-title":"Variants of SARS CoV-2: mutations, transmissibility, virulence, drug resistance, and antibody\/vaccine sensitivity","volume":"27","author":"Prubeta","year":"2022","journal-title":"Front. Biosci. (Landmark Ed.)"},{"key":"10.1016\/j.jconrel.2023.04.029_bb0015","doi-asserted-by":"crossref","DOI":"10.3390\/pathogens11080823","article-title":"Prescription of anti-spike monoclonal antibodies in COVID-19 patients with resistant SARS-CoV-2 variants in Italy","volume":"11","author":"Focosi","year":"2022","journal-title":"Pathogens"},{"key":"10.1016\/j.jconrel.2023.04.029_bb0020","series-title":"Features, Evaluation, and Treatment of Coronavirus (COVID-19)","author":"Cascella","year":"2022"},{"key":"10.1016\/j.jconrel.2023.04.029_bb0025","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1038\/s41577-021-00542-x","article-title":"Neutralizing monoclonal antibodies for treatment of COVID-19","volume":"21","author":"Taylor","year":"2021","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.jconrel.2023.04.029_bb0030","article-title":"SARS-CoV-2-neutralising monoclonal antibodies for treatment of COVID-19","volume":"9","author":"Kreuzberger","year":"2021","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.jconrel.2023.04.029_bb0035","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1038\/s41577-020-0311-8","article-title":"The trinity of COVID-19: immunity, inflammation and intervention","volume":"20","author":"Tay","year":"2020","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.jconrel.2023.04.029_bb0040","article-title":"Therapeutic activity of an inhaled potent SARS-CoV-2 neutralizing human monoclonal antibody in hamsters","volume":"2","author":"Piepenbrink","year":"2021","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.jconrel.2023.04.029_bb0045","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/s41392-022-01135-3","article-title":"A potent neutralizing antibody provides protection against SARS-CoV-2 omicron and Delta variants via nasal delivery","volume":"7","author":"Zhang","year":"2022","journal-title":"Signal. Transduct. Target. Ther."},{"key":"10.1016\/j.jconrel.2023.04.029_bb0050","doi-asserted-by":"crossref","first-page":"15517","DOI":"10.1038\/s41598-022-19780-7","article-title":"Unbiased approach to identify and assess efficacy of human SARS-CoV-2 neutralizing antibodies","volume":"12","author":"Cao","year":"2022","journal-title":"Sci. Rep."},{"key":"10.1016\/j.jconrel.2023.04.029_bb0055","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1186\/s12879-022-07513-0","article-title":"Anti-SARS-CoV2 antibody-mediated cytokine release syndrome in a patient with acute promyelocytic leukemia","volume":"22","author":"Hegazy","year":"2022","journal-title":"BMC Infect. Dis."},{"key":"10.1016\/j.jconrel.2023.04.029_bb0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2022.121704","article-title":"Dual targeting powder formulation of antiviral agent for customizable nasal and lung deposition profile through single intranasal administration","volume":"619","author":"Seow","year":"2022","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2023.04.029_bb0065","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.1007\/s11095-022-03331-w","article-title":"Spray-dried and spray-freeze-dried powder formulations of an anti-interleukin-4Ralpha antibody for pulmonary delivery","volume":"39","author":"Pan","year":"2022","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jconrel.2023.04.029_bb0070","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1016\/j.addr.2011.08.003","article-title":"Protein stabilization by cyclodextrins in the liquid and dried state","volume":"63","author":"Serno","year":"2011","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2023.04.029_bb0075","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.ijpharm.2017.07.013","article-title":"Inhaled powder formulation of naked siRNA using spray drying technology with l-leucine as dispersion enhancer","volume":"530","author":"Chow","year":"2017","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2023.04.029_bb0080","doi-asserted-by":"crossref","first-page":"615","DOI":"10.3390\/pharmaceutics13050615","article-title":"Inhalable protein powder prepared by spray-freeze-drying using Hydroxypropyl-beta-Cyclodextrin as excipient","volume":"13","author":"Lo","year":"2021","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.jconrel.2023.04.029_bb0085","article-title":"Comparative analysis of SARS-CoV-2 omicron BA.2.12.1 and BA.5.2 variants","volume":"95","author":"Ong","year":"2022","journal-title":"J. Med. Virol."},{"key":"10.1016\/j.jconrel.2023.04.029_bb0090","article-title":"Intratracheal Administration of dry Powder Formulation in mice","volume":"161","author":"Qiu","year":"2020","journal-title":"J. Vis. Exp."},{"key":"10.1016\/j.jconrel.2023.04.029_bb0095","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.jconrel.2019.10.026","article-title":"Effective mRNA pulmonary delivery by dry powder formulation of PEGylated synthetic KL4 peptide","volume":"314","author":"Qiu","year":"2019","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2023.04.029_bb0100","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.ijpharm.2015.01.015","article-title":"First in vivo evaluation of particulate nasal dry powder vaccine formulations containing ovalbumin in mice","volume":"479","author":"Scherliess","year":"2015","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2023.04.029_bb0105","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1038\/s41564-020-00802-x","article-title":"Metallodrug ranitidine bismuth citrate suppresses SARS-CoV-2 replication and relieves virus-associated pneumonia in Syrian hamsters","volume":"5","author":"Yuan","year":"2020","journal-title":"Nat. Microbiol."},{"key":"10.1016\/j.jconrel.2023.04.029_bb0110","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1126\/science.abn8939","article-title":"Pathogenicity, transmissibility, and fitness of SARS-CoV-2 omicron in Syrian hamsters","volume":"377","author":"Yuan","year":"2022","journal-title":"Science"},{"key":"10.1016\/j.jconrel.2023.04.029_bb0115","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1038\/s41421-021-00338-2","article-title":"SARS-CoV-2 exploits host DGAT and ADRP for efficient replication","volume":"7","author":"Yuan","year":"2021","journal-title":"Cell Discov."},{"key":"10.1016\/j.jconrel.2023.04.029_bb0120","doi-asserted-by":"crossref","first-page":"e503","DOI":"10.1093\/cid\/ciaa995","article-title":"Severe acute respiratory syndrome coronavirus 2 infects and damages the mature and immature olfactory sensory neurons of hamsters","volume":"73","author":"Zhang","year":"2021","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.jconrel.2023.04.029_bb0125","article-title":"Oral SARS-CoV-2 inoculation establishes subclinical respiratory infection with virus shedding in Golden Syrian hamsters","volume":"1","author":"Lee","year":"2020","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.jconrel.2023.04.029_bb0130","doi-asserted-by":"crossref","first-page":"eaba7910","DOI":"10.1126\/sciadv.aba7910","article-title":"Viruses harness YxxO motif to interact with host AP2M1 for replication: A vulnerable broad-spectrum antiviral target","volume":"6","author":"Yuan","year":"2020","journal-title":"Sci. Adv."},{"key":"10.1016\/j.jconrel.2023.04.029_bb0135","doi-asserted-by":"crossref","first-page":"6315","DOI":"10.1007\/s00253-021-11488-4","article-title":"Inhalation monoclonal antibody therapy: a new way to treat and manage respiratory infections","volume":"105","author":"Parray","year":"2021","journal-title":"Appl. Microbiol. Biotechnol."},{"key":"10.1016\/j.jconrel.2023.04.029_bb0140","article-title":"Real-world evidence of neutralizing monoclonal antibodies for preventing hospitalization and mortality in COVID-19 outpatients","author":"Wynia","year":"2022","journal-title":"Chest"},{"key":"10.1016\/j.jconrel.2023.04.029_bb0145","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.tips.2022.11.006","article-title":"Inhalable neutralizing antibodies - promising approach to combating respiratory viral infections","volume":"44","author":"Chow","year":"2023","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.jconrel.2023.04.029_bb0150","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/s41586-022-05053-w","article-title":"Antibody evasion by SARS-CoV-2 omicron subvariants BA.2.12.1, BA.4 and BA.5","volume":"608","author":"Wang","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.jconrel.2023.04.029_bb0155","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.addr.2020.12.004","article-title":"Challenges and opportunities for antiviral monoclonal antibodies as COVID-19 therapy","volume":"169","author":"Cruz-Teran","year":"2021","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2023.04.029_bb0160","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1208\/s12249-021-02095-7","article-title":"Local treatment of non-small cell lung Cancer with a spray-dried bevacizumab formulation","volume":"22","author":"Shepard","year":"2021","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.jconrel.2023.04.029_bb0165","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.ejpb.2022.07.013","article-title":"Inhalable microparticle platform based on a novel shell-forming lipid excipient and its feasibility for respirable delivery of biologics","volume":"177","author":"Wang","year":"2022","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.jconrel.2023.04.029_bb0170","doi-asserted-by":"crossref","first-page":"4121","DOI":"10.1002\/jps.23729","article-title":"Influence of hydroxypropyl-Beta-cyclodextrin on the stability of dilute and highly concentrated immunoglobulin g formulations","volume":"102","author":"Hartl","year":"2013","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2023.04.029_bb0175","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2020.120121","article-title":"Development of a formulation platform for a spray-dried, inhalable tuberculosis vaccine candidate","volume":"593","author":"Gomez","year":"2021","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2023.04.029_bb0180","doi-asserted-by":"crossref","first-page":"2384","DOI":"10.1016\/j.drudis.2021.04.009","article-title":"Leucine as an excipient in spray dried powder for inhalation","volume":"26","author":"Alhajj","year":"2021","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.jconrel.2023.04.029_bb0185","series-title":"Drug Discovery and Development","article-title":"Intranasal drug administration \u2014 An attractive delivery route for some drugs","author":"Degenhard","year":"2015"},{"key":"10.1016\/j.jconrel.2023.04.029_bb0190","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ijpharm.2019.03.004","article-title":"A Design of Experiment (DoE) approach to optimise spray drying process conditions for the production of trehalose\/leucine formulations with application in pulmonary delivery","volume":"562","author":"Focaroli","year":"2019","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2023.04.029_bb0195","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1038\/s41591-020-0868-6","article-title":"Network, SARS-CoV-2 entry factors are highly expressed in nasal epithelial cells together with innate immune genes","volume":"26","author":"Sungnak","year":"2020","journal-title":"Nat. Med."},{"key":"10.1016\/j.jconrel.2023.04.029_bb0200","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.cell.2020.05.042","article-title":"SARS-CoV-2 reverse genetics reveals a variable infection gradient in the respiratory tract","volume":"182","author":"Hou","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.jconrel.2023.04.029_bb0205","doi-asserted-by":"crossref","DOI":"10.3389\/fphys.2022.842592","article-title":"Regional differences in Mucociliary clearance in the upper and lower airways","volume":"13","author":"Rogers","year":"2022","journal-title":"Front. Physiol."},{"key":"10.1016\/j.jconrel.2023.04.029_bb0210","doi-asserted-by":"crossref","first-page":"2300","DOI":"10.1016\/j.drudis.2022.04.012","article-title":"Engineered nasal dry powder for the encapsulation of bioactive compounds","volume":"27","author":"Baldelli","year":"2022","journal-title":"Drug Discov. Today"}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365923002791?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365923002791?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T17:51:55Z","timestamp":1764870715000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365923002791"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":42,"alternative-id":["S0168365923002791"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2023.04.029","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Neutralisation of SARS-CoV-2 by monoclonal antibody through dual targeting powder formulation","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2023.04.029","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}